ArticleScientific reports2025
Exploring the antibacterial efficacy of Opuntia monacantha in combatting methicillin-resistant Staphylococcus aureus.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Public health is seriously threatened by the rise of antibiotic-resistant strains of bacteria, especially methicillin resistant Staphylococcus aureus (MRSA). This study investigated the phytochemical compounds, and possible antibacterial effects of a methanolic extract of the cactus species Opuntia monacantha Haw. against MRSA. The powdered substance was extracted with methanol and filtered, and the filtrate was partitioned with n-hexane, chloroform and ethyl acetate. The fractions with higher percentage yields such as the n-hexane and chloroform fractions went through GC-MS analysis. They consist of various compounds that are known to have strong antioxidant and antimicrobial activities. The antimicrobial activity of the plant was measured via a diffusion assay. On the basis of these results, the Opuntia monacantha crude methanolic extract, and the n-hexane and chloroform fractions significantly inhibited all the MRSA strains used in the test at 100, 75 and 50 mg/mL. Furthermore, the minimum inhibitory concentrations of various fractions of the methanolic extract of Opuntia monacantha were also examined. Therefore, Opuntia could be a promising candidate for strengthening the existing formulations in pharmaceutical science for the treatment of MRSA. However, additional research is necessary before its therapeutic use is recommended. The results are intended to provide important new information for the creation of sustainable and alternative antimicrobial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.